Chemotherapy News and Research

Latest Chemotherapy News and Research

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Access to dermatologist improves melanoma-related health outcomes

Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a non-dermatologist, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007

New player in the development T-cell acute lymphoblastic leukemia

Leuven, Belgium -- Leukemia, or cancer of the bone marrow, strikes some 700 Belgians each year.

16 Apr 2007

New tumor antigen found with new cloning technique

In recent years, researchers have worked to develop a number of vaccines to help the immune system fight tumors.

16 Apr 2007

Functional diffusion map measures effectiveness of treatment for prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.

16 Apr 2007

New chemical agent, MCP110, provides synergistic effect to standard drugs

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

16 Apr 2007

Investigational cancer 17-AAG drug targets critical proteins

A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.

16 Apr 2007

Eating well still one of the best ways to prevent cancer and promote good health

We all know that eating fruits, vegetables and soy products provides essential nutrition for a healthy lifestyle, while obesity leads to the opposite.

16 Apr 2007

New device to test for proteins that play important role in human health and disease

A new technology developed at the University of Toronto is revealing biochemical processes responsible for diseases such as cystic fibrosis and could one day pave the way for pharmaceutical applications.

15 Apr 2007

Gleevec shows great promise in preventing cancer recurrence

Gleevec, a pill developed in conjunction with the Oregon Health & Science University Cancer Institute is again showing excellent results in preventing a cancer recurrence.

15 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Gleevec decreases cancer recurrence for GIST

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.

15 Apr 2007